Bradly Bauman
Postdoctoral AssociateAbout
Research
Publications
2026
A Novel Dominant-negative CARD11 Variant Causes Atopy and Immunodeficiency Syndrome
Le K, Lindsay B, Bauman B, Kettunen K, Ylinen A, Kaustio M, Kesti T, Mamia N, Heiskanen K, Martelius T, Huttunen P, Milner J, Seppänen M, Saarela J, Snow A, Grönholm J. A Novel Dominant-negative CARD11 Variant Causes Atopy and Immunodeficiency Syndrome. Journal Of Clinical Immunology 2026 DOI: 10.1007/s10875-026-02070-6.Peer-Reviewed Original ResearchA Novel Intronic Deletion Causing “Deficiency in ELF4, X-Linked”
Bauman B, Kumar D, Khanna-Gupta A, Kribis M, Begtrup A, Lopez E, Lucas C. A Novel Intronic Deletion Causing “Deficiency in ELF4, X-Linked”. Journal Of Human Immunity 2026, 2 DOI: 10.70962/cis2026abstract.120.Peer-Reviewed Original ResearchThe CARD11–BCL10–MALT1 (CBM) Complex Regulates Nutrient Transport and mTORC1 Activation to Shape CD4+ T Cell Differentiation
Ruchinskas A, Bauman B, Kallarakal M, Milner J, Petit V, Sitbon M, Taylor N, Snow A. The CARD11–BCL10–MALT1 (CBM) Complex Regulates Nutrient Transport and mTORC1 Activation to Shape CD4+ T Cell Differentiation. Journal Of Human Immunity 2026, 2 DOI: 10.70962/cis2026abstract.225.Peer-Reviewed Original Research
2025
Functional validation of PIK3R1 variant causing activated phosphoinositide 3-kinase-δ syndrome 2 with hypogammaglobulinemia and bronchiectasis
Kribis M, Bauman B, Dutmer C, Abbott J, Catanzaro J, Lucas C. Functional validation of PIK3R1 variant causing activated phosphoinositide 3-kinase-δ syndrome 2 with hypogammaglobulinemia and bronchiectasis. Journal Of Human Immunity 2025, 1: e20250085. PMID: 42169763, PMCID: PMC13177672, DOI: 10.70962/jhi.20250085.Peer-Reviewed Original ResearchA novel CARD11 heterozygous missense variant in a CADINS patient
AlYafie R, Adeli M, Velayutham D, Bougarn S, Ata M, Al-Ali F, Chin-Smith E, Bauman B, Snow A, Boisson B, Marr N, van Panhuys N, Guennoun A, Jithesh P. A novel CARD11 heterozygous missense variant in a CADINS patient. Journal Of Allergy And Clinical Immunology Global 2025, 4: 100461. PMID: 40275935, PMCID: PMC12018100, DOI: 10.1016/j.jacig.2025.100461.Peer-Reviewed Original ResearchDominant interfering CARD11 variants disrupt JNK signaling to promote GATA3 expression in T cells
Bauman B, Stinson J, Kallarakal M, Huang L, Frank A, Sukumar G, Saucier N, Dalgard C, Chan A, Milner J, Cooper M, Snow A. Dominant interfering CARD11 variants disrupt JNK signaling to promote GATA3 expression in T cells. Journal Of Experimental Medicine 2025, 222: e20240272. PMID: 40111223, PMCID: PMC11924952, DOI: 10.1084/jem.20240272.Peer-Reviewed Original Research
2024
A20 intrinsically influences human effector T‐cell survival and function by regulating both NF‐κB and JNK signaling
Dabbah‐Krancher G, Ruchinskas A, Kallarakal M, Lee K, Bauman B, Epstein B, Yin H, Krappmann D, Schaefer B, Snow A. A20 intrinsically influences human effector T‐cell survival and function by regulating both NF‐κB and JNK signaling. European Journal Of Immunology 2024, 54: e2451245-e2451245. PMID: 39359035, PMCID: PMC11631677, DOI: 10.1002/eji.202451245.Peer-Reviewed Original ResearchManagement of Atopy with Dupilumab and Omalizumab in CADINS Disease
Diaz-Cabrera N, Bauman B, Iro M, Dabbah-Krancher G, Molho-Pessach V, Zlotogorski A, Shamriz O, Dinur-Schejter Y, Sharon T, Stepensky P, Tal Y, Eisenstein E, Pietzsch L, Schuetz C, Abreu D, Coughlin C, Cooper M, Milner J, Williams A, Armoni-Weiss G, Snow A, Leiding J. Management of Atopy with Dupilumab and Omalizumab in CADINS Disease. Journal Of Clinical Immunology 2024, 44: 48. PMID: 38231347, DOI: 10.1007/s10875-023-01636-y.Peer-Reviewed Original Research
2023
Subcutaneous panniculitis-like T-cell lymphoma in two unrelated individuals with BENTA disease
Bauman B, Dorjbal B, Pittaluga S, Zhang Y, Niemela J, Stoddard J, Rosenzweig S, Anderson R, Guilcher G, Auer I, Perrier R, Campbell M, Bhandal S, Alba C, Sukumar G, Dalgard C, Schelotto M, Wright N, Su H, Snow A. Subcutaneous panniculitis-like T-cell lymphoma in two unrelated individuals with BENTA disease. Clinical Immunology 2023, 255: 109732. PMID: 37562721, PMCID: PMC10551883, DOI: 10.1016/j.clim.2023.109732.Peer-Reviewed Original Research
2021
TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1
Lake C, Voss K, Bauman B, Pohida K, Jiang T, Dveksler G, Snow A. TIM-3 drives temporal differences in restimulation-induced cell death sensitivity in effector CD8+ T cells in conjunction with CEACAM1. Cell Death & Disease 2021, 12: 400. PMID: 33854046, PMCID: PMC8046753, DOI: 10.1038/s41419-021-03689-6.Peer-Reviewed Original Research